CD105 expression is an independent predictor of survival in patients with endometrial cancer

Erdem O., Taskiran C., Onan M. A., Erdem M., Guner H., Ataoglu O.

GYNECOLOGIC ONCOLOGY, vol.103, no.3, pp.1007-1011, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 103 Issue: 3
  • Publication Date: 2006
  • Doi Number: 10.1016/j.ygyno.2006.06.010
  • Journal Name: GYNECOLOGIC ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1007-1011
  • Keywords: angiogenesis, CD105, CD34, VEGF, endometrial cancer, survival, ENDOTHELIAL GROWTH-FACTOR, TUMOR ANGIOGENESIS, BREAST-CARCINOMA, PROGNOSTIC INDICATOR, ENDOGLIN CD105, CELL MARKERS, VASCULATURE, HYPERPLASIA, CD34
  • Gazi University Affiliated: Yes

Abstract

Objective. The purpose of this study was to detect the prognostic value of CD105 (endoglin) and also to compare with CD34 and vascular endothelial growth factor (VEGF) in patients with endometrial adenocancer.